The company's pursuit of a tighter research focus follows a path very much like that of its peers.
AstraZeneca and Roche strike antibiotic deals.
Monday's announcement builds on a stream of recent R&D relationships.
The midnight shutdown put 800,000 government employees on leave, including those at the FDA, NIH and CDC.
GSK sees a regulatory setback on its once-weekly GLP-1 med, and Spectrum Pharma gets hit with an untitled letter from OPDP on a sales aid for Zevalin.
Companies are moving toward more access to clinical trial data. Despite their new stance, the internal battles haven't quite ended, some say.
Quarterly sales fell 11% compared to the same period last year. The company plans on weathering a continued flow of patent losses with a narrower R&D focus.
The drug maker's third round of testing will focus on mild Alzheimer's patients. Candidates must test positive for beta amyloid.
China alleges GSK foul play; a report links Incyte's Jakafi with PML; Pfizer gets a double-dose of good Prevnar news; Europe puts almost $29B toward research.
A two-year study shows Gilead's Quad pill outpaces an older combination drug over two years, and GSK is seeking to expand its oncology presence.
Astellas teams up with Cytokinetics for muscle weakness research; ADA says lifestyle changes don't protect diabetics' hearts; AJMC talks pharmacists as diabetes counselors; and AARP helps with healthcare reform education.
Studies undercut Medtronic spine treatment benefit, AMA wars over obesity classification, Komen gets a new CEO, GSK offloads thrombosis meds, Lilly gains diabetes treatment, AZN chooses new site
Roger Perlmutter has begun to trim the fat off Merck's lackluster pipeline.
Novartis is advancing its "breakthrough" lung cancer drug into Phase III based on promising Phase I data.
GSK's newest cancer approvals highlight a problem that stalks progress with personalized medicines.
Merck's proposed insomnia drug scores a thumbs-up from an FDA advisory panel, and long-time Forest Labs CEO Howard Solomon announces his coming retirement.
GSK and the US Department of Health and Human Services inked a deal to fund development of new antibiotics, an area where clinicians face a dearth of new options.
It was a particularly grim Monday for 200 Astellas employees in the US, who were informed that they were being let go and it was their last day with the company.
The regulatory coup means BMS gets to work with FDA to develop its home-grown hep. C cocktail, which is on a competitive track to another hep. C alliance with Merck.
Phase III findings on sofosbuvir, released in a medical journal, suggest no cause for concern from a safety perspective.
FDA is accelerating review of Pfizer's experimental breast cancer drug palbociclib, which analysts say already has a fan base among KOLs.
BMS fills week's end with shakeup and collaboration news, European regulators tamp down on rare disease drug pricing, association estimates pharma wooed UK docs with $61 million in gifts last year.
Days after announcing a sharp downsizing, the patent expiry-plagued company said it will eliminate an additional 2,300 jobs, raising the tally of cuts to more than 5,000 through 2016.
AstraZeneca is cutting 650 jobs in the US, "primarily in R&D," and consolidating its R&D operations at three "strategic R&D centers" in "bioscience clusters," academic and industrial beehives where the company can tap into concentrations of talent and infrastructure.
CMS issued its long-delayed final rule for collecting data on industry payments to physicians, ordering data collection to begin in August and asserting that the federal law preempts state laws.
AstraZeneca jettisoned its global head of commercial operations and R&D chief, eliminating their roles and curtly suctioning off the company's second-highest layer of management.
The J&J diabetes drug seems effective in getting glucose down but may bump up bad cholesterol, raising a red flag for FDA advisory committee members.
Boehringer Ingelheim doubles down on one diabetes treatment, while parting ways on another; and Merck closes the year as a force in the start-up market.
Transparency Life Sciences is tapping the wisdom of the crowd, with FDA's imprimatur, in an effort to make the drug development process more sustainable.
Researchers said the industry closed 2012 with a mixed bag of results. The upside: more approvals than last year. The downside: projected sales for these new drugs is less.